Payment overview · 2025
General Payments
$929.17
44 reported records · 20 companies
Healthcare provider profile · identity verified
Robert Chance Algar, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · WALNUT CREEK, CA · NPI 1750343729
Verified facts
What the public records show
CMS Open Payments records show Robert Chance Algar, MD received $929.17 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Inbrija, Nurtec Odt.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xarelto by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INBRIJA as an associated drug or biological on 4307 records involving 2211 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Inbrija by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.32 | 16.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.65 | 13.4% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $83.75 | 9.0% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.25 | 7.2% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $52.86 | 5.7% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.70 | 5.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.63 | 5.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.18 | 5.0% | 2 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $40.21 | 4.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.21 | 3.7% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $31.92 | 3.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $29.64 | 3.2% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.35 | 3.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $22.49 | 2.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.52 | 2.2% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.13 | 2.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.29 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.25 | 2.0% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.13 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.69 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $929.17 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $121.18 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.18 | 11 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $105.74 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $83.75 | 5 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $67.25 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $49.63 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $46.18 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $34.21 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $32.14 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $31.92 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $31.92 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $29.84 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INBRIJA inbrija |
2025 | Inbrija | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | INBRIJA open payments reported associated product |
CMS Open Payments — General Payments 4307 supporting records · 2211 recipient NPIs · example record 1232555387 |
Inbrija · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 304 | 79 |
| Donepezil Hcl | Donepezil Hcl | 239 | 67 |
| Memantine Hcl | Memantine Hcl | 194 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 37 |
| Sertraline Hcl | Sertraline Hcl | 152 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 140 | 38 |
| Trazodone Hcl | Trazodone Hcl | 136 | 28 |
| Levetiracetam | Levetiracetam | 134 | 43 |
| Meloxicam | Meloxicam | 128 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 28 |
| Rasagiline Mesylate | Rasagiline Mesylate | 100 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 20 |
| Baclofen | Baclofen | 85 | 25 |
| Pregabalin | Pregabalin | 83 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 83 | 20 |
| Tramadol Hcl | Tramadol Hcl | 83 | 22 |
| Lamotrigine | Lamotrigine | 75 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 72 | 15 |
| Primidone | Primidone | 66 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 20 |
| Risperidone | Risperidone | 51 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 46 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 21 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Modafinil | Modafinil | 35 | suppressed |
| Topiramate | Topiramate | 35 | 12 |
| Emgality Pen | Galcanezumab-Gnlm | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | 11 |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 28 | suppressed |
| Teriflunomide | Teriflunomide | 26 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Clobazam | Clobazam | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Zolmitriptan | Zolmitriptan | 21 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Inbrija | Levodopa | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $929.17 · 44 records | ABBVIE INC. | BOTOX, BRIUMVI, EMGALITY, General - DBS, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, NUPLAZID, NURTEC ODT, Ocrevus, Ocrevus Zunovo, PONVORY, QULIPTA, REXULTI, Radicava, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VYEPTI, WAINUA, Xeomin, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Inbrija play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error